miRNAs as potential markers for breast cancer and regulators of tumorigenesis and progression (Review)
- Authors:
- Hongxiang Mu
- Wenmao Zhang
- Ye Qiu
- Ting Tao
- Hongliang Wu
- Zhuo Chen
- Gaosheng Xu
-
Affiliations: Yueyang Maternal and Child Health Hospital, Yueyang, Hunan 414000, P.R. China - Published online on: March 3, 2021 https://doi.org/10.3892/ijo.2021.5196
- Article Number: 16
This article is mentioned in:
Abstract
 |
|
Ding L, Li J, Wu C, Yan F, Li X and Zhang S: A self-assembled RNA-triple helix hydrogel drug delivery system targeting triple-negative breast cancer. J Mater Chem B. 8:3527–3533. 2020. View Article : Google Scholar | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Song Y, Wang Z, Zhang Z, Lu M and Wang Y: Long Non-coding RNA LINC01787 drives breast cancer progression via disrupting miR-125b generation. Front Oncol. 9:11402019. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W, Yu M, Lin J and Cui Q: MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance and applications in human triple-negative breast cancer. Cells. 8:14922019. View Article : Google Scholar | |
|
Denkiewicz M, Saha I, Rakshit S, Sarkar JP and Plewczynski D: Identification of breast cancer subtype specific MicroRNAs using survival analysis to find their role in transcriptomic regulation. Front Genet. 10:10472019. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao Y, Humphries B, Yang C and Wang Z: MiR-205 Dysregulations in breast cancer: The complexity and opportunities. Noncoding RNA. 5:532019. | |
|
Ediriweera MK and Cho SK: Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer. Pharmacol Ther. 206:1074372020. View Article : Google Scholar | |
|
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J and Shi B: Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 5:2929–2943. 2015.PubMed/NCBI | |
|
Kapadia CH, Ioele SA and Day ES: Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells. J Biomed Mater Res A. 108:601–613. 2020. View Article : Google Scholar : | |
|
Tian Y, Xia S, Ma M and Zuo Y: LINC00096 promotes the proliferation and invasion by sponging miR-383-5p and regulating RBM3 expression in triple-negative breast cancer. Onco Targets Ther. 12:10569–10578. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng S, Li M, Miao K and Xu H: lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. J Cell Biochem. 121:2225–2235. 2020. View Article : Google Scholar | |
|
Umeh-Garcia M, Simion C, Ho PY, Batra N, Berg AL, Carraway KL, Yu A and Sweeney C: A novel bioengineered miR-127 prodrug suppresses the growth and metastatic potential of triple-negative breast cancer cells. Cancer Res. 80:418–429. 2020. View Article : Google Scholar | |
|
Das PK, Siddika MA, Asha SY, Aktar S, Rakib MA, Khanam JA, Pillai S and Islam F: MicroRNAs, a promising target for breast cancer stem cells. Mol Diagn Ther. 24:69–83. 2020. View Article : Google Scholar | |
|
Ge JH, Zhu JW, Fu HY, Shi WB and Zhang CL: An antisense oligonucleotide drug targeting miR-21 induces H1650 apoptosis and caspase activation. Technol Cancer Res Treat. 18:15330338198922632019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Ann Rev Pathol. 9:287–314. 2014. View Article : Google Scholar | |
|
Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Abdolvahabi Z, Nourbakhsh M, Hosseinkhani S, Hesari Z, Alipour M, Jafarzadeh M, Ghorbanhosseini SS, Seiri P, Yousefi Z, Yarahmadi S and Golpour P: MicroRNA-590-3P suppresses cell survival and triggers breast cancer cell apoptosis via targeting sirtuin-1 and deacetylation of p53. J Cell Biochem. 120:9356–9368. 2019. View Article : Google Scholar | |
|
Shaffi SK, Galas D, Etheridge A and Argyropoulos C: Role of MicroRNAs in renal parenchymal diseases-a new dimension. Int J Mol Sci. 19:17972018. View Article : Google Scholar | |
|
Chen E, Xu X, Liu R and Liu T: Small but heavy role: MicroRNAs in hepatocellular carcinoma progression. Biomed Res Int. 2018:67846072018.PubMed/NCBI | |
|
Svoronos AA, Engelman DM and Slack FJ: OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Wang Q, Zhong H, Li L, Zhang Q, Huang Q and Yu Z: Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. Oncol Rep. 43:240–250. 2020. | |
|
Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : | |
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Visone R and Croce CM: MiRNAs and cancer. Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Reis-Filho JS, Weigelt B, Fumagalli D and Sotiriou C: Molecular profiling: Moving away from tumor philately. Sci Transl Med. 2:47ps432010. View Article : Google Scholar : PubMed/NCBI | |
|
Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Yu H, Qiao Y, Yang J, Shu J, Zhang J, Zhang Z, He J and Li Z: Salivary Glycopatterns as potential biomarkers for screening of early-stage breast cancer. EBioMedicine. 28:70–79. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, et al: Prognostic value of a BCSC-associated MicroRNA signature in hormone receptor-positive HER2-negative breast cancer. EBioMedicine. 11:199–209. 2016. View Article : Google Scholar : | |
|
Do SI, Kim HS, Kim K, Lee H, Do IG, Kim DH, Chae SW and Sohn JH: Predictive and prognostic value of sphingosine kinase 1 expression in patients with invasive ductal carcinoma of the breast. Am J Transl Res. 9:5684–5695. 2017. | |
|
Phillips SL, Williams CB, Zambrano JN, Williams CJ and Yeh ES: Connexin 43 in the development and progression of breast cancer: What's the connection? (Review) Int J Oncol. 51:1005–1013. 2017. View Article : Google Scholar | |
|
Katoh M: Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 51:1357–1369. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Javadian M, Shekari N, Soltani-Zangbar MS, Mohammadi A, Mansoori B, Maralbashi S, Shanehbandi D, Baradaran B, Darabi M and Kazemi T: Docosahexaenoic acid suppresses migration of triple-negative breast cancer cell through targeting metastasis-related genes and microRNA under normoxic and hypoxic conditions. J Cell Biochem. 121:2416–2427. 2020. View Article : Google Scholar | |
|
Zhao CH, Qu L, Zhang H and Qu R: Identification of breast cancer-related circRNAs by analysis of microarray and RNA-sequencing data: An observational study. Medicine. 98:e180422019. View Article : Google Scholar : PubMed/NCBI | |
|
Tang W, Li GS, Li JD, Pan WY, Shi Q, Xiong DD, Mo CH, Zeng JJ, Chen G, Feng ZB, et al: The role of upregulated miR-375 expression in breast cancer: An in vitro and in silico study. Pathol Res Pract. 216:1527542020. View Article : Google Scholar | |
|
Tungsukruthai S, Petpiroon N and Chanvorachote P: Molecular mechanisms of breast cancer metastasis and potential Anti-metastatic compounds. Anticancer Res. 38:2607–2618. 2018.PubMed/NCBI | |
|
Li X, Dai D, Chen B, Tang H, Xie X and Wei W: Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast cancer. Oncol Lett. 16:4679–4688. 2018.PubMed/NCBI | |
|
Duffy MJ, Evoy D and McDermott EW: CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 411:1869–1874. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xie S, Ding X, Mo W and Chen J: Serum tissue polypeptide-specific antigen is an independent predictor in breast cancer. Acta Histochem. 116:372–376. 2014. View Article : Google Scholar | |
|
Duffy MJ: Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem. 52:345–351. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Weigel MT and Dowsett M: Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Guo S, Zhang J, Wang B, Zhang B, Wang X, Huang L, Liu H and Jia B: A 5-serum miRNA panel for the early detection of colorectal cancer. Onco Targets Ther. 11:2603–2614. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Adams BD, Arem H, Hubal MJ, Cartmel B, Li F, Harrigan M, Sanft T, Cheng CJ, Pusztai L and Irwin ML: Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Res Treat. 170:55–67. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Paszek S, Gabło N, Barnaś E, Szybka M, Morawiec J, Kołacińska A and Zawlik I: Dysregulation of microRNAs in triple-negative breast cancer. Ginekol Pol. 88:530–536. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One. 5:e137352010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang N, Wang L, Yang Y, Gong L, Xiao B and Liu X: A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. Biochem Biophys Res Commun. 493:1322–1328. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Wen W, Zhu J, Huang Z, Zhang L, Zhang H, Qi LW, Shan X, Wang T, Cheng W, et al: A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget. 8:34468–34480. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S and Mokarian F: Plasma level of miR-21 and miR-451 in primary and recurrent breast cancer patients. Breast Cancer (Dove Med Press). 11:293–301. 2019. | |
|
Raheem AR, Abdul-Rasheed OF and Al-Naqqash MA: The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer. Saudi Med J. 40:1218–1226. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Xu L, He L, Wang J, Shi X, Li Z, Shi S, Hou K, Teng Y and Qu X: MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer. J Cancer. 11:3771–3782. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu B, Liu G, Jin Y, Yang T, Zhang D, Ding L, Zhou F, Pan Y and Wei Y: miR-15b-5p promotes growth and metastasis in breast cancer by targeting HPSE2. Front Oncol. 10:1082020. View Article : Google Scholar : PubMed/NCBI | |
|
Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K and Ju J: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 13:1668–1674. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Treiber T, Treiber N and Meister G: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar | |
|
Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids Res. 36:D154–D158. 2008. View Article : Google Scholar : | |
|
Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T and Margalit H: Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 33:2697–2706. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH and Kim VN: MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23:4051–4060. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kim VN: MicroRNA precursors in motion: Exportin-5 mediates their nuclear export. Trends Cell Biol. 14:156–159. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S and Kim VN: The nuclear RNase III Drosha initiates microRNA processing. Nature. 425:415–419. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N and Shiekhattar R: The Microprocessor complex mediates the genesis of microRNAs. Nature. 432:235–240. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lund E, Güttinger S, Calado A, Dahlberg JE and Kutay U: Nuclear export of microRNA precursors. Science. 303:95–98. 2004. View Article : Google Scholar | |
|
Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G and Mello CC: Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 106:23–34. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bernstein E, Caudy AA, Hammond SM and Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 409:363–366. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T and Zamore PD: A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 293:834–838. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Parker R and Song H: The enzymes and control of eukaryotic mRNA turnover. Nat Struct Mol Biol. 11:121–127. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mathe A, Scott RJ and Avery-Kiejda KA: MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer. Int J Mol Sci. 16:28347–28376. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Petersen CP, Bordeleau ME, Pelletier J and Sharp PA: Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 21:533–542. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S and Lu HC: microRNAs in Neurodegeneration: Current findings and potential impacts. J Alzheimers Dis Parkinsonism. 8:4202018. View Article : Google Scholar : PubMed/NCBI | |
|
Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ma F, Liu X, Li D, Wang P, Li N, Lu L and Cao X: MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation. J Immunol. 184:6053–6059. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A, Jadidi-Niaragh F, Yousefi M, Kafil HS, Bastami M, et al: MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. J Cell Physiol. 235:5008–5029. 2020. View Article : Google Scholar | |
|
Tavakolian S, Goudarzi H, Eslami G and Faghihloo E: Transcriptional regulation of epithelial to mesenchymal transition related genes by lipopolysaccharide in human cervical cancer cell line HeLa. Asian Pac J Cancer Prev. 20:2455–2461. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Pourbagheri-Sigaroodi A, Bashash D, Safaroghli-Azar A, Farshi-Paraasghari M, Momeny M, Mansoor FN and Ghaffari SH: Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line. Eur J Pharmacol. 846:49–62. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W and Luo YP: MicroRNAs in breast cancer: Oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B. 16:18–31. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, Moriya S, Idichi T, Maemura K, Fujii T, et al: RNA-sequence-based microRNA expression signature in breast cancer: Tumor-suppressive miR-101-5p regulates molecular pathogenesis. Mol Oncol. 14:426–446. 2020. View Article : Google Scholar | |
|
Ma J and Zhou Z: Downregulation of miR-302b is associated with poor prognosis and tumor progression of breast cancer. Breast Cancer. 27:291–298. 2020. View Article : Google Scholar | |
|
Tavakolian S, Goudarzi H, Torfi F and Faghihloo E: Evaluation of microRNA-9 and -192 expression levels as biomarkers in patients suffering from breast cancer. Biomed Rep. 12:30–34. 2020. | |
|
Sun WM, Tao W, Li JC, Zhu DM and Miao Y: MicroRNA-296 functions as a tumor suppressor in breast cancer by targeting FGFR1 and regulating the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 23:10422–10432. 2019.PubMed/NCBI | |
|
Cai F, Chen L, Sun Y, He C, Fu D and Tang J: MiR-539 inhibited the malignant behaviors of breast cancer cells by targeting SP1. Biochem Cell Biol. 98:426–433. 2020. View Article : Google Scholar | |
|
Cai WL, Huang WD, Li B, Chen TR, Li ZX, Zhao CL, Li HY, Wu YM, Yan WJ and Xiao JR: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 17:92018. View Article : Google Scholar : PubMed/NCBI | |
|
Niu XY, Zhang ZQ and Ma PL: MiRNA-221-5p promotes breast cancer progression by regulating E-cadherin expression. Eur Rev Med Pharmacol Sci. 23:6983–6990. 2019.PubMed/NCBI | |
|
Orangi E and Motovali-Bashi M: Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women. Gene. 687:272–279. 2019. View Article : Google Scholar | |
|
Jiang H, Cheng L, Hu P and Liu R: MicroRNA-663b mediates TAM resistance in breast cancer by modulating TP73 expression. Mol Med Rep. 18:1120–1126. 2018.PubMed/NCBI | |
|
Aoki N, Amano S, Ando M, Fukuda A, Ami K, Imai K, Ganno H, Sugita H, Amagasa H, Arai K, et al: A study of therapy for locally advanced breast cancer with metastasis. Gan To Kagaku Ryoho. 43:1432–1434. 2016.In Japanese. | |
|
Anderson GM: Breast-cancer recurrence after stopping endocrine therapy. N Engl J Med. 378:8702018. View Article : Google Scholar : PubMed/NCBI | |
|
Neophytou C, Boutsikos P and Papageorgis P: Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol. 8:312018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang L, Tang X, Shi X and Su L: miR-532-5p promotes breast cancer proliferation and migration by targeting RERG. Exp Ther Med. 19:400–408. 2020. | |
|
Robertson NM and Yigit MV: The role of microRNA in resistance to breast cancer therapy. Wiley Interdiscip Rev RNA. 5:823–33. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J, Swensen J and Gatalica Z: Potential novel therapy targets in neuroendocrine carcinomas of the breast. Clin Breast Cancer. 19:131–136. 2019. View Article : Google Scholar | |
|
Ang D, Ballard M, Beadling C, Warrick A, Schilling A, O'Gara R, Pukay M, Neff TL, West RB, Corless CL and Troxell ML: Novel mutations in neuroendocrine carcinoma of the breast: Possible therapeutic targets. Appl Immunohistochem Mol Morphol. 23:97–103. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, et al: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res. 11:7434–7443. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shackelford RE, Mayhall K, Maxwell NM, Kandil E and Coppola D: Nicotinamide phosphoribosyltransferase in malignancy: A review. Genes Cancer. 4:447–456. 2013. View Article : Google Scholar | |
|
Grolla AA, Travelli C, Genazzani AA and Sethi JK: Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine. Br J Pharmacol. 173:2182–2194. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bolandghamat Pour Z, Nourbakhsh M, Mousavizadeh K, Madjd Z, Ghorbanhosseini SS, Abdolvahabi Z, Hesari Z and Ezzati Mobasser S: Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin. BMC Cancer. 19:10272019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Yang L, Guo X, Jin G, Wang Q, Lv D, Liu J, Chen Q, Song Q and Li B: Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep. 18:455–460. 2018.PubMed/NCBI | |
|
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nie H, Xie X, Zhang D, Zhou Y, Li B, Li F, Li F, Cheng Y, Mei H, Meng H and Jia L: Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. Nanoscale. 12:877–887. 2020. View Article : Google Scholar | |
|
Li XJ, Ren ZJ, Tang JH and Yu Q: Exosomal MicroRNA MiR-1246 promotes cell proliferation, invasion and drug resistance by targeting CCNG2 in breast cancer. Cell Physiol Biochem. 44:1741–1748. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Dai Y, Zhang X and Chen J: Three-layered polyplex as a microRNA targeted delivery system for breast cancer gene therapy. Nanotechnology. 28:2851012017. View Article : Google Scholar : PubMed/NCBI | |
|
Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H and Kianmehr M: Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol. 233:5200–5213. 2018. View Article : Google Scholar | |
|
Zarredar H, Ansarin K, Baradaran B, Shekari N, Eyvazi S, Safari F and Farajnia S: Critical microRNAs in lung cancer: Recent advances and potential applications. Anticancer Agents Med Chem. 18:1991–2005. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Markowitz GJ and Wang X: Noncoding RNAs regulating cancer signaling network. Adv Exp Med Biol. 927:297–315. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zhou S, Mao L, Zhang H, Sun D, Zhang J, Li J and Tang JH: Crosstalk between TGF-beta signaling and miRNAs in breast cancer metastasis. Tumour Biol. 37:10011–10019. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Smith B, Agarwal P and Bhowmick NA: MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr Relat Cancer. 24:R157–R172. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kia V, Sharif Beigli M, Hosseini V, Koochaki A, Paryan M and Mohammadi-Yeganeh S: Is miR-144 an effective inhibitor of PTEN mRNA: A controversy in breast cancer. In vitro Cell Dev Biol Anim. 54:621–628. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yue D and Qin X: miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Ther. 26:1–10. 2019. View Article : Google Scholar | |
|
Zhang Y, Zhao Z, Li S, Dong L, Li Y, Mao Y, Liang Y, Tao Y and Ma J: Inhibition of miR-214 attenuates the migration and invasion of triple-negative breast cancer cells. Mol Med Rep. 19:4035–4042. 2019.PubMed/NCBI | |
|
Samadi P, Saki S, Dermani FK, Pourjafar M and Saidijam M: Emerging ways to treat breast cancer: Will promises be met? Cell Oncol (Dordr). 41:605–621. 2018. View Article : Google Scholar | |
|
Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S, Luo G, Liu P, Liu J, Du N, et al: Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells. Cell Cycle. 14:1686–1697. 2015. View Article : Google Scholar : | |
|
Zhao Y, Yang F, Li W, Xu C, Li L, Chen L, Liu Y and Sun P: miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. Tumour Biol. 39:10104283176922642017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R and Nakshatri H: Systemic actions of breast cancer facilitate functional limitations. Cancers. 12:1942020. View Article : Google Scholar : | |
|
Ruan L and Qian X: MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway. Biosci Rep. 39:BSR201916112019. View Article : Google Scholar | |
|
D'Souza LC, Mishra S, Chakraborty A, Shekher A, Sharma A and Gupta SC: Oxidative stress and cancer development: Are noncoding RNAs the missing links? Antioxid Redox Signal. 33:1209–1229. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mohammady M, Ghetmiri SI, Baharizade M, Morowvat MH and Torabi S: Expanding the Biotherapeutics realm via miR-34a: 'Potent Clever Little' agent in breast cancer therapy. Curr Pharm Biotechnol. 20:665–673. 2019. View Article : Google Scholar | |
|
Pan JY, Zhang F, Sun CC, Li SJ, Li G, Gong FY, Bo T, He J, Hua RX, Hu WD, et al: miR-134: A human cancer suppressor? Mol Ther Nucleic Acids. 6:140–149. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Majumder M, Dunn L, Liu L, Hasan A, Vincent K, Brackstone M, Hess D and Lala PK: COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Sci Rep. 8:3272018. View Article : Google Scholar : PubMed/NCBI | |
|
Zou Y, Lin X, Bu J, Lin Z, Chen Y, Qiu Y, Mo H, Tang Y, Fang W and Wu Z: Timeless-Stimulated miR-5188-FOXO1/β-Catenin-c-Jun feedback loop promotes stemness via Ubiquitination of β-catenin in breast cancer. Mol Ther. 28:313–327. 2020. View Article : Google Scholar | |
|
Han B, Peng X, Cheng D, Zhu Y, Du J, Li J and Yu X: Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA-34a axis. Cancer Sci. 110:3089–3097. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ju J, Zhu AJ and Yuan P: Progress in targeted therapy for breast cancer. Chronic Dis Transl Med. 4:164–175. 2018.PubMed/NCBI | |
|
Liu H, Li A, Sun Z, Zhang J and Xu H: Long non-coding RNA NEAT1 promotes colorectal cancer progression by regulating miR-205-5p/VEGFA axis. Hum Cell. 33:386–396. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kaban K, Salva E and Akbuga J: Modulation of the dual-faced effects of miR-141 with chitosan/miR-141 nanoplexes in breast cancer cells. J Gene Med. 21:e31162019. View Article : Google Scholar : PubMed/NCBI | |
|
Han M, Wang F, Gu Y, Pei X, Guo G, Yu C, Li L, Zhu M, Xiong Y and Wang Y: MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncol Rep. 35:73–80. 2016. View Article : Google Scholar | |
|
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L and Yu H: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 117:131–140. 2009. View Article : Google Scholar | |
|
Citron F, Segatto I, Vinciguerra GLR, Musco L, Russo F, Mungo G, D'Andrea S, Mattevi MC, Perin T, Schiappacassi M, et al: Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer. Cancer Res. 80:1064–1077. 2020. View Article : Google Scholar | |
|
Lee A, Moon BI and Kim TH: BRCA1/BRCA2 pathogenic variant breast cancer: Treatment and prevention strategies. Ann Lab Med. 40:114–121. 2020. View Article : Google Scholar | |
|
Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, et al: Open-label clinical trial of Niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5:1132–1140. 2019. View Article : Google Scholar : | |
|
Wang X and Liu Y: PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathol Res Pract. 216:1528022020. View Article : Google Scholar : PubMed/NCBI | |
|
Yahya SM and Elsayed GH: A summary for molecular regulations of miRNAs in breast cancer. Clin Biochem. 48:388–396. 2015. View Article : Google Scholar | |
|
Grelet S and Howe PH: hnRNP E1 at the crossroads of translational regulation of epithelial-mesenchymal transition. J Cancer Metastasis Treat. 5:162019.PubMed/NCBI | |
|
Campbell K and Casanova J: A common framework for EMT and collective cell migration. Development. 143:4291–4300. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schaeffer D, Somarelli JA, Hanna G, Palmer GM and Garcia-Blanco MA: Cellular migration and invasion uncoupled: Increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition. Mol Cell Biol. 34:3486–3499. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Son H and Moon A: Epithelial-mesenchymal transition and cell invasion. Toxicol Res. 26:245–252. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wardhani BW, Puteri MU, Watanabe Y, Louisa M, Setiabudy R and Kato M: TGF-β-induced TMEPAI attenuates the response of triple-negative breast cancer cells to doxorubicin and paclitaxel. J Exp Pharmacol. 12:17–26. 2020. View Article : Google Scholar : | |
|
Wang S, Huang M, Wang Z, Wang W, Zhang Z, Qu S and Liu C: MicroRNA-133b targets TGFβ receptor I to inhibit TGF-β-induced epithelial-to-mesenchymal transition and metastasis by suppressing the TGF-β/SMAD pathway in breast cancer. Int J Oncol. 55:1097–1109. 2019.PubMed/NCBI | |
|
Zeng Y, Gao T, Huang W, Yang Y, Qiu R, Hou Y, Yu W, Leng S, Feng D, Liu W, et al: MicroRNA-455-3p mediates GATA3 tumor suppression in mammary epithelial cells by inhibiting TGF-β signaling. J Biol Chem. 294:15808–15825. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guerrero-Zotano A, Mayer IA and Arteaga CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell. 170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Xu JJ and Zhang QY: MicroRNA-132-3p inhibits tumor malignant progression by regulating lysosomal-associated protein transmembrane 4 beta in breast cancer. Cancer Sci. 110:3098–3109. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Li R, Shi W, Jiang T, Wang Y, Li C and Qu X: Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother. 77:37–44. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Wang H and Yang Z: MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS One. 7:e470532012. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson KN, Whipple RA, Yoon JR, Lipsky M, Charpentier MS, Boggs AE, Chakrabarti KR, Bhandary L, Hessler LK, Martin SS and Vitolo MI: The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence. Oncotarget. 6:35231–35246. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Carlomagno F and Chiariello M: Growth factor transduction pathways: Paradigm of anti-neoplastic targeted therapy. J Mol Med (Berl). 92:723–733. 2014. View Article : Google Scholar | |
|
Osaki LH and Gama P: MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci. 14:10143–10161. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston SR, Semiglazov VF, Manikhas GM, Spaeth D, Romieu G, Dodwell DJ, Wardley AM, Neven P, Bessems A, Park YC, et al: A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. 110:327–335. 2008. View Article : Google Scholar | |
|
Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye F and Xie X, Chen J, Tang H and Xie X: miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 6:34968–34978. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Xu W, Luo Y, Zhang Y, He Y, Yang S and Yuan Z: MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK/MAPK. Onco Targets Ther. 10:1423–1431. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13. 2013. View Article : Google Scholar : | |
|
Wu H, Wang G, Wang Z, An S, Ye P and Luo S: A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells. FEBS J. 283:2259–2271. 2016. View Article : Google Scholar | |
|
Xie M, Fu Z, Cao J, Liu Y, Wu J, Li Q and Chen Y: MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer. Biomed Pharmacother. 102:286–294. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Wang YX, Chen LP and Ji ML: Upregulation of microRNA-181b inhibits CCL18-induced breast cancer cell metastasis and invasion via the NF-κB signaling pathway. Oncol Lett. 12:4411–4418. 2016. View Article : Google Scholar | |
|
Senthil Kumar KJ, Gokila Vani M, Hsieh HW, Lin CC, Liao JW, Chueh PJ and Wang SY: MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer tumorigenesis and metastasis via downregulation of NF-κB signaling. Carcinogenesis. 40:335–348. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H, Li X, Wang W and Dong H: Long non-coding RNA SNHG3 promotes breast cancer cell proliferation and metastasis by binding to microRNA-154-3p and activating the notch signaling pathway. BMC Cancer. 20:8382020. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Huang T, Liu Z, Sun M and Luo S: LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. Eur J Pharmacol. 856:1724072019. View Article : Google Scholar : PubMed/NCBI | |
|
Lan L, Wang Y, Pan Z, Wang B, Yue Z, Jiang Z, Li L, Wang C and Tang H: Rhamnetin induces apoptosis in human breast cancer cells via the miR-34a/Notch-1 signaling pathway. Oncol Lett. 17:676–682. 2019.PubMed/NCBI | |
|
Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, Zhao L, Li J, Yang B and Li L: MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci. 106:700–708. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li WJ, Xie XX, Bai J, Wang C, Zhao L and Jiang DQ: Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 22:8374–8382. 2018.PubMed/NCBI | |
|
Ren L, Chen H, Song J, Chen X, Lin C, Zhang X, Hou N, Pan J, Zhou Z, Wang L, et al: MiR-454-3p-Mediated Wnt/β-catenin signaling Antagonists suppression promotes breast cancer metastasis. Theranostics. 9:449–465. 2019. View Article : Google Scholar : | |
|
Xie Q, Wang S, Zhao Y, Zhang Z, Qin C and Yang X: MicroRNA-216a suppresses the proliferation and migration of human breast cancer cells via the Wnt/β-catenin signaling pathway. Oncol Rep. 41:2647–2656. 2019.PubMed/NCBI | |
|
Liu S, Wang Z, Liu Z, Shi S, Zhang Z, Zhang J and Lin H: miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer. J Mol Cell Biol. 10:302–315. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tan Z, Zheng H, Liu X, Zhang W, Zhu J, Wu G, Cao L, Song J, Wu S, Song L and Li J: MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer. Oncotarget. 7:24076–24087. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Liu Y, Shen J, Zhang G and Han J: MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating Fizzled 5 expression. Oncotarget. 7:49130–49142. 2016. View Article : Google Scholar : PubMed/NCBI |
